Taiwan's Central Epidemic Command Center (CECC) has recently ordered a monoclonal antibody (mAb)-based drug used to treat mild to moderate COVID-19 in patients and expects to receive delivery by mid-June.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan vanilla products recognized by international institute
04/17/2024 10:21 PM - Sports
Dominican pitcher receives CPBL lifetime ban after failing drug test
04/17/2024 09:13 PM - Society
Weather front to bring rain, cooler temperatures overnight
04/17/2024 08:43 PM - Society
Demolition of building damaged in Hualien earthquake completed
04/17/2024 08:36 PM - Business
Taiwan's semiconductor industry output forecast to grow over 13% in 2024
04/17/2024 08:09 PM